Lymphoma Clinical Trials in Cleveland

Showing 361-380 of 573 trials

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

NCT02567656

The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.

Lymphoma, T-Cell, PeripheralLymphoma, T-Cell, Cutaneous

Rhizen Pharmaceuticals SA58 participantsStarted Sep 2015

Duarte, California, United States • Orange, California, United States • Aurora, Colorado, United States +5 more locations

TERMINATEDPhase 1< 1 mile

Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas

NCT03119467

A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients with Relapsed or Refractory Lymphomas

Lymphoma

Rhizen Pharmaceuticals SA21 participantsStarted May 2017

Birmingham, Alabama, United States • Duarte, California, United States • Aurora, Colorado, United States +8 more locations

COMPLETED25 miles

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

NCT01110733

Prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices.

Peripheral T-cell Lymphoma

Acrotech Biopharma Inc.3,000 participantsStarted Feb 2010

Tuscaloosa, Alabama, United States • Tucson, Arizona, United States • Hot Springs, Arkansas, United States +65 more locations

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Lymphoma Trials in Other Cities

Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma

Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL

Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma

Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)

Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL

Other Conditions in Cleveland